ProCE Banner Activity

Randomized Phase II Trial of VK2809, an Investigational Thyroid Hormone Receptor Agonist, vs Placebo in NAFLD With Hyperlipidemia

Slideset Download
Conference Coverage
Patients treated with VK2809 for 12 weeks showed significantly reduced LDL-C and liver fat content vs those treated with placebo.

Released: April 22, 2019

Expiration: April 20, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

AbbVie

Gilead